首都医科大学附属北京天坛医院位于北京市丰台区南四环西路119号，始建于1956年8月23日，占地面积181581平方米，总建筑面积 352294平方米，是一所以神经外科为先导，以神经科学集群为特色，集医疗、教学、科研、预防为一体的三级甲等综合医院。

药学部是集临床服务、科研、教学和管理为一体的服务于全院的平台科室，由门诊西药房、中心药房、门诊中药房、临床药学、个体化治疗中心、药物临床试验机构药等部门组成。职员工共131人，其中博士后1名，博士15名，硕士13名，本科以上学历约占65%，其中主任药师4名，副主任药师14名。

除了科研人员的引进与培训，科室先后购置快速血药浓度检测仪(TDx)、全自动化学发光免疫分析仪(AXSYM)、3台液质联用仪、基因测序设备和超高相液相分析仪，科室有独立的细胞房。已与神经病学中心、ICU、心内科和神经外科等科室联合开展20多个合作项目。

药学部承担累计100多项研究课题，获得经费支持超1500万，其中十一五和十三五子课题各1项，863子课题1项，国家自然科学基金5项，北京自然科学基金2项。累计发表SCI论文180余篇，中文论文800余篇，共有5名药师获得国家自然科学基金；两名药师获得北京市医院管理中心“青苗”人才项目；3名药师获得北京市医管局“培育”计划。

1.        北京市医管局培育计划，整合代谢物-基因-预测模型的PCNSL甲氨蝶呤精准治疗，PX2024020，15万元，2024/1-2026/12，在研，主持

2.        横向临床药动学研究课题，康替唑胺片在确诊或拟诊中枢神经系统感染的神经外科术后受试者的脑脊液穿透性及药代动力学研究，KY2022-249-03，9.99万元，2023/6-2025/6，在研，主持

3.        中国健康促进基金会，多粘菌素E人血浆和脑脊液中检测方法建立及临床应用，Z021001，10万元，2022/10/01-2025/12/31，在研，主持

4.        国家自然科学基金面上项目，82173894，整合代谢酶-转运体-肠道微生物多因素研究巯嘌呤治疗ALL中活性代谢产物TGNs的调控及巯嘌呤纳米粒的干预，2022/01/01-2025/12/31，55万元，在研，参与

5.        国家重点研发计划“主动健康和老龄化科技应对”“基于肝药酶基因与药物代谢模型的老年人个体化用药智能决策系统的建立”，2020YFC2008306，子课题6“老年人个体化用药仿真模拟系统及临床用药决策支持平台建设”，2020/12-2023/11，17.56万元，在研，参与(排名第8)

6.        北京市人才工作局优秀人才资助青年骨干项目，2018000021469G238，NUDT15 基因多态性对硫唑嘌呤代谢和药效的影响，2018/08-2021/08，6万元，结题，主持

7.        首都医科大学科研培育基金(自然类)，PYZ2017113，基于药物基因组学的拉莫三嗪治疗儿童癫痫的群体药动学/药效学研究，2018/01-2018/12，5万元，结题，主持

8.        北京市医管局扬帆计划，ZYLX201827，神经系统药物治疗，2018/01-2020/12，100万元，结题，参与(骨干、完成9篇SCI论文)

9.        北京市自然科学基金重点项目，7171004，基于定量药理学的巯嘌呤缓释微片技术及其应用研究，2017/01-2020/12，80万元，结题，参与(骨干、排名第3)

10.    国家自然科学基金青年项目，81503157，P2RY12基因多态性及启动子区DNA甲基化对氯吡格雷抵抗的影响机制与定量研究，2016/01-2018/12，21.48万元，结题，参与

11.    国家自然科学基金青年项目，81301118，基于药物基因组学的丙戊酸钠治疗童癫痫的群体PPK/PPD模型研究，2014/01-2016/12，23万元，结题，参与(骨干、排名第3)

1.       北京市医管局培育计划，整合代谢物-基因-预测模型的PCNSL甲氨蝶呤精准治疗，PX2024020，15万元，2024/1-2026/12，在研，主持

2.       横向临床药动学研究课题，康替唑胺片在确诊或拟诊中枢神经系统感染的神经外科术后受试者的脑脊液穿透性及药代动力学研究，KY2022-249-03，9.99万元，2023/6-2025/6，在研，主持

3.       中国健康促进基金会，多粘菌素E人血浆和脑脊液中检测方法建立及临床应用，Z021001，10万元，2022/10/01-2025/12/31，在研，主持

4.       国家自然科学基金面上项目，82173894，整合代谢酶-转运体-肠道微生物多因素研究巯嘌呤治疗ALL中活性代谢产物TGNs的调控及巯嘌呤纳米粒的干预，2022/01/01-2025/12/31，55万元，在研，参与

5.       国家重点研发计划“主动健康和老龄化科技应对”“基于肝药酶基因与药物代谢模型的老年人个体化用药智能决策系统的建立”，2020YFC2008306，子课题6“老年人个体化用药仿真模拟系统及临床用药决策支持平台建设”，2020/12-2023/11，17.56万元，在研，参与(排名第8)

6.       北京市人才工作局优秀人才资助青年骨干项目，2018000021469G238，NUDT15 基因多态性对硫唑嘌呤代谢和药效的影响，2018/08-2021/08，6万元，结题，主持

7.       首都医科大学科研培育基金(自然类)，PYZ2017113，基于药物基因组学的拉莫三嗪治疗儿童癫痫的群体药动学/药效学研究，2018/01-2018/12，5万元，结题，主持

8.       北京市医管局扬帆计划，ZYLX201827，神经系统药物治疗，2018/01-2020/12，100万元，结题，参与(骨干、完成9篇SCI论文)

9.       北京市自然科学基金重点项目，7171004，基于定量药理学的巯嘌呤缓释微片技术及其应用研究，2017/01-2020/12，80万元，结题，参与(骨干、排名第3)

10.   国家自然科学基金青年项目，81503157，P2RY12基因多态性及启动子区DNA甲基化对氯吡格雷抵抗的影响机制与定量研究，2016/01-2018/12，21.48万元，结题，参与

11.   国家自然科学基金青年项目，81301118，基于药物基因组学的丙戊酸钠治疗童癫痫的群体PPK/PPD模型研究，2014/01-2016/12，23万元，结题，参与(骨干、排名第3)

1.        XingmengLi(#), Shifeng Wei(#), Han Wu, Qiang Zhang, Zhigang Zhao,Shenghui Mei(*), Weixing Feng(*), Yun Wu(*). Population pharmacokinetics ofoxcarbazepine active metabolite in Chinese children with epilepsy. EuropeanJournal of Pediatrics, 2023, doi: 10.1007/s00431-023-05092-z.

2.        ShifengWei(#), Xingmeng Li(#), Qiang Zhang, Han Wu, Yun Wu,Zhigang Zhao(*), Shenghui Mei(*), Weixing Feng(*). Population pharmacokineticsof topiramate in Chinese children with epilepsy. European Journal of ClinicalPharmacology, 2023, doi: 10.1007/s00228-023-03549-6.

3.        HuoJiping(#), Guo Yangyang(#), Zhang Bo, Zhao Zhigang, ShiGuangzhi(*), MeiShenghui(*). A UHPLC-MS/MS method for the simultaneous determinationof vancomycin, norvancomycin, meropenem, and moxalactam in human plasma and itsclinical application. J Mass Spectrom. 2023;58(6):e4925.

4.        JiangRuiqi(#), Zhang Dongjie(#), Zhao Zhigang(*), Mei Shenghui(*).Simultaneous determination of 24 antiepileptic drugs and their activemetabolites in human plasma by UHPLC-MS/MS. J Pharm Biomed Anal.2023;232:115437.

5.        WeiShifeng(#), Chen Jingcheng(#), Zhao Zhigang(*), Mei Shenghui(*).External validation of population pharmacokinetic models of vancomycin inpostoperative neurosurgical patients. Eur J Clin Pharmacol. 2023; 79(8):1031-1042.Doi:10.1007/s00228-023-03511-6.

6.        ShifengWei, Dongjie Zhang, Zhigang Zhao(*), Shenghui Mei(*).Population pharmacokineticmodel of vancomycin in postoperative neurosurgical patients. Frontiers inPharmacology. 2022, 13:1005791. doi: 10.3389/fphar.2022.1005791

7.        YangHua, Zhang Dongjie, Mei Shenghui(*), Zhao Zhigang(*).Simultaneous determination of plasma lamotrigine, lamotrigine N2-glucuronideand lamotrigine N2-oxide by UHPLC-MS/MS in epileptic patients. J Pharm BiomedAnal. 2022;220:115017.

8.        RuiqiJiang, ShenghuiMei(*), Zhigang Zhao(*). Leucovorin (folinicacid) rescue for high-dose methotrexate: A review. Journal of Clinical Pharmacyand Therapeutics, 2022, 47(9):1452-1460.doi: 10.1111/jcpt.13739.

9.        JiangRuiqi, Yang Jiayu, Mei Shenghui(*), Zhao Zhigang(*).Determination of levodopa by chromatography-based methods in biologicalsamples: a review. Anal Sci. 2022;38(8):1009-17.

10.     Jin Siyao(#), Pang Wenyuan(#),Zhao Libo, Zhao Zhigang, Mei Shenghui(*). Review of HPLC-MSmethods for the analysis of nicotine and its active metabolite cotinine invarious biological matrices. Biomed Chromatogr. 2022; 36(6):e5351. Doi: 10.1002/bmc.5351:e5351.

11.     Yiming Zhang(#), Liyu Sun(#),Xinwei Chen, Libo Zhao, Xiaoling Wang, Zhigang Zhao(*), Shenghui Mei(*).A Systematic Review of Population Pharmacokinetic Models of Methotrexate.European Journal of Drug Metabolism and Pharmacokinetics, 2022, 47(2):143-164. doi: 10.1007/s13318-021-00737-6.

12.     Qing Zhao(#), Yong Cui(#),Chun Zeng, Xiaohui Ren, Kefu Yu, Song Lin, Zhigang Zhao, Shenghui Mei(*).Association between SNPs and hepatotoxicity in patients with primary centralnervous system lymphoma on high-dose methotrexate therapy. Journal of Pharmacy and Pharmacology, 2021, 73(11):1480-1490. doi: 10.1093/jpp/rgab099.

13.     Yiming Zhang(#), Liyu Sun, LiboZhao, Xiaoling Wang, Zhigang Zhao(*), Shenghui Mei(*).Methotrexate Polyglutamates Analysis by Chromatography Methods in BiologicalMatrices: A Review. Analytical Sciences:The International Journal of the Japan Society for Analytical Chemistry,2021, 37(12):1655-1664. doi: 10.2116/analsci.21R001.

14.     Qing Zhao(#), Siyao Jin(#),Qingyang Liu(#), Zhigang Zhao, Weixing Feng, Shenghui Mei(*).Simultaneous Determination of Lamotrigine, Topiramate, Oxcarbazepine, and10,11-dihydro-10-hydroxycarbazepine in Human Blood Plasma by UHPLC-MS/MS. Current Analytical Chemistry, 2020,16(8): 1010-1021.

15.    Mei Shenghui(#), Cui Yong(#), Zhang Dongjie, Zeng Chun,Ren Xiaohui, Yu Kefu, Lin Song(*), Zhao Zhigang(*).Simultaneous determination of urine methotrexate, 7-hydroxy methotrexate,deoxyaminopteroic acid, and 7-hydroxy deoxyaminopteroic acid by UHPLC-MS/MS inpatients receiving high-dose methotrexate therapy. Analytical Sciences:The International Journal of the Japan Society for Analytical Chemistry, 2020, 36(12):1479-1483. doi: 10.2116/analsci.19P481. Impactfactor: 2.049

16.    Han Jiaqi(#),Mei Shenghui(#),Xu Jiamin, Zhang Dongjie, Jin Siyao, Zhao Zhigang(*), Zhao Libo(*).Simultaneous UPLC-MS/MS Determination of 6-mercaptopurine,6-methylmercaptopurine and 6-thioguanine in Plasma: Application to thePharmacokinetic Evaluation of Novel Dosage forms in Beagle Dogs. Current Pharmaceutical Design, 2020, 26(46):6013-6020.doi: 10.2174/1381612826999200820161343. Impact factor: 2.208

17.    HanNannan(#)，Jia Lu，Guo Lijia，Su Yingying，LuoZhenhua，Du Juan，Mei Shenghui(*)，Liu Yi(*).Balanced oral pathogenic bacteria and probiotics promoted wound healing viamaintaining mesenchymal stem cell homeostasis. Stem Cell Research & Therapy,2020, 11(1): 61. Impact factor: 4.627

18.    SiyaoJin(#), Qing Zhao(#), Dongjie Zhang, Zhigang Zhao, Shenghui Mei(*).Development and validation of an improved HPLC-UV method for simultaneousdetermination of lamotrigine and oxcarbazepine and its active metabolite10,11-dihydro-10-hydroxycarbazepine in human blood plasma and comparison withan UHPLC-MS/MS method. Journal ofAnalytical Science and Technology, 2019,10(1): 10. Impact factor: 1.66

19.    LiuYang(#), Zhang Dongjie(#), Du Juan, Qin Ying, ZhaoZhigang, Shi Yanjun, Mei Shenghui(*),Liu Yi(*). Simultaneous determination of plasma nicotine andcotinine by UHPLC-MS/MS in C57BL/6 mice and its application in apharmacokinetic study. BiomedChromatogr. 2019; 33(10):e4634. Doi: 10.1002/bmc.4634. Impact factor: 1.748

20.    GuoShanshan(#), Mei Shenghui(#), Wang Qiaoyu, LiXingang, Chen Yang, He Qiyang(*), Zhao Zhigang(*).Determination of cantharidic acid in rat blood by microdialysis combined withUHPLC–MS/MS. International Journal ofMass Spectrometry. 2019;440:20-6. Impact factor: 1.826

21.    Shenghui Mei(#), Jiaqing Wang(#), Di Chen(#),Leting Zhu, Ming Zhao, Xin Hu, Li Yang, Zhigang Zhao(*), Ultra-HighPerformance Liquid Chromatography Tandem Mass Spectrometry for CyclosporineAnalysis in Human Whole Blood and Comparison With an Antibody-ConjugatedMagnetic Immunoassay, Therapeutic DrugMonitoring, 2018, 40(1), 69-75.Impact factor: 2.092

22.    Shenghui Mei(#), Xiaoxu Shi(#), Yaming Du, Yong Cui, ChunZeng, Xiaohui Ren, Kefu Yu, Zhigang Zhao(*), Song Lin(*),Simultaneous determination of plasma methotrexate and 7-hydroxy methotrexate byUHPLC-MS/MS in patients receiving high-dose methotrexate therapy, Journal of Pharmaceutical and BiomedicalAnalysis, 2018, 158: 300-306.Impact factor: 2.831

23.    Shenghui Mei(#), Jiaqing Wang(#), Di Chen(#),Leting Zhu, Ming Zhao, Xiaoxin Tian, Xin Hu(*), Zhigang Zhao(*),Simultaneous determination of cyclosporine and tacrolimus in human whole bloodby ultra-high performance liquid chromatography tandem mass spectrometry andcomparison with a chemiluminescence microparticle immunoassay, Journal of Chromatography B, 2018, 1087-1088: 36-42. Impact factor:2.441

24.    Shenghui Mei(#), Weixing Feng(#), Leting Zhu, Xingang Li,Yazhen Yu, Weili Yang, Baoqin Gao, Xiaojuan Wu, Fang Fang(*),Zhigang Zhao(*). Effect of CYP2C19, UGT1A8, and UGT2B7 onvalproic acid clearance in children with epilepsy: a population pharmacokineticmodel. Eur J Clin Pharmacol.2018, Doi:10.1007/s00228-018-2440-6. Impact factor: 2.679

25.    WeixingFeng(#), Shenghui Mei(#), Jiaqi Han(#),Leting Zhu, Yazhen Yu, Baoqin Gao, Yun Wu, Jiuwei Li, Zhigang Zhao(*),Fang Fang(*). Lack of association between valproic acid response andpolymorphisms of its metabolism, transport, and receptor genes in children withfocal seizures. Neurological Sciences.2018;Doi: 10.1007/s10072-018-3681-y.Impact factor: 2.285

26.    WeixingFeng(#), Shenghui Mei(#), Leting Zhu, YazhenYu, Weili Yang, Baoqin Gao, Xiaojuan Wu, Zhigang Zhao(*), Fang Fang(*).Effects of UGT2B7, SCN1A and CYP3A4 on the therapeutic response of sodiumvalproate treatment in children with generalized seizures. Seizure. 2018, 58:96-100. Impact factor: 2.839

27.    Shenghui Mei(#), Xingang Li, Xueyun Jiang, Kefu Yu, Song Lin(*),Zhigang Zhao(*), Population pharmacokinetics of high-dosemethotrexate in patients with primary central nervous system lymphoma, Journal of Pharmaceutical Sciences, 2018, Doi: 10.1016/j.xphs.2018.01.004.Impact factor: 3.075

28.    Shenghui Mei(#), Leting Zhu(#), Xingang Li, Jiaqing Wang,Xueyun Jiang, Haiyan Chen, Jiping Huo, Li Yang, Song Lin(*), ZhigangZhao(*), UPLC-MS/MS Analysis of Methotrexate in Human Plasma andComparison with the Fluorescence Polarization Immunoassay, Analytical Sciences: The International Journal of the Japan Society forAnalytical Chemistry, 2017,33(6), 665-670. Impact factor: 1.355

29.    Shenghui Mei(#), Jiaqing Wang(#), Leting Zhu, Ruiling Chen,Xingang Li, Kai Chen, Guangqiang Chen, Jianxin Zhou, Qiang Wang(*),Zhigang Zhao(*), A UPLC-MS/MS method for analysis of vancomycin inhuman cerebrospinal fluid and comparison with the chemiluminescenceimmunoassay, Biomedical Chromatography,2017, 31(8). Impact factor: 1.688

30.    Shenghui Mei(#), Jiaqing Wang(#), Qing Cheng, Leting Zhu,Li Yang, Ruiling Chen(*), Zhigang Zhao(*), Development,validation, and application of an UPLC-MS/MS method for norvancomycin analysisin human blood plasma, Journal of Chromatography.B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1072, 199-204. Impact factor:2.441

31.    Shenghui Mei(#), Xindi Li(#), Xiaoqing Gong, Xiaoyi Zhang,Xingang Li, Li Yang, Leting Zhu, Heng Zhou, Yonghong Liu, Anna Zhou, XinghuZhang(*), Zhigang Zhao(*), Comparison of 6-mercaptopurinewith 6-thioguanine for the analysis of thiopurine S-methyltransferase activityin human erythrocyte by LC-MS/MS, BiomedicalChromatography, 2017, 31(9),Impact factor: 1.688

32.    Shenghui Mei(#), Xindi Li(#), Xiaoqing Gong, Xingang Li,Li Yang, Heng Zhou, Yonghong Liu, Anna Zhou, Leting Zhu, Xinghu Zhang(*),Zhigang Zhao, LC-MS/MS Analysis of Erythrocyte Thiopurine Nucleotides and TheirAssociation With Genetic Variants in Patients With Neuromyelitis Optica SpectrumDisorders Taking Azathioprine, TherapeuticDrug Monitoring, 2017, 39(1),5-12. Impact factor: 2.092

33.    Shenghui Mei(#), Weixing Feng(#), Leting Zhu, Yazhen Yu,Weili Yang, Baoqin Gao, Xiaojuan Wu, Zhigang Zhao(*), Fang Fang(*),Genetic polymorphisms and valproic acid plasma concentration in children withepilepsy on valproic acid monotherapy, Seizure,2017, 51, 22-26. Impact factor:2.839

34.    WeixingFeng(#), Shenghui Mei(#), Leting Zhu, YazhenYu, Weili Yang, Baoqin Gao, Xiaojuan Wu, Zhigang Zhao(*), Fang Fang(*),Effects of UGT1A6 and GABRA1 on Standardized Valproic Acid PlasmaConcentrations and Treatment Effect in Children With Epilepsy in China, Therapeutic Drug Monitoring, 2016, 38(6), 738-743. Impact factor:2.14

35.    Shenghui Mei(#), Xuying Luo(#), Xingang Li, Qian Li,Jiping Huo, Li Yang, Leting Zhu, Weixing Feng, Jianxin Zhou, Guangzhi Shi(*),Zhigang Zhao(*), Development and validation of an LC-MS/MS methodfor the determination of tigecycline in human plasma and cerebrospinal fluidand its application to a pharmacokinetic study, Biomedical Chromatography, 2016,30(12), 1992-2002. Impact factor: 1.55

36.    Shenghui Mei(#), Jiawang Liu(#), Ming Zhao(*),Wenjing Wang, Yuji Wang, Guofeng Wu, Meiqing Zheng, Shiqi Peng(*),From Cerius(2) based stereoview to mouse and enzyme: the model systems fordiscovery of novel urokinase inhibitors, MolecularBiosystems, 2011, 7(9),2664-2669. Impact factor: 3.534